Clinical trial
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And…
NCT00143455 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00143455 |
|---|---|
| Title | Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer |
| Official title | Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Etoposide + cisplatin, Irinotecan + cisplatin |
| Enrollment | 485 |
| Start date | Jun 1, 2002 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 2, 2005 |
| Last update posted | Feb 18, 2010 |
| Countries | Austria, Belgium, Czechia, Egypt, France, Germany, Italy, Netherlands, Poland, Russia, Spain, Switzerland and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: